Manas’s story

Consumer Brand Commercial Due Diligence: Holding the Line on a PE Deal Thesis

Surfaced a structural flaw in a PE fund's acquisition thesis and reframed the deal without killing it.

Manas C.

Associate Manager at EY-Parthenon

EEY-Parthenon
BBoston Consulting Group (BCG)
DDefence Research and Development Organisation (DRDO)
NNetaji Subhas Institute of Technology
4+ years of experience

From their time as

E

Associate Manager

EY-Parthenon β€’ 2026

Overview

Manas was brought in to run commercial due diligence for a global PE fund on a consumer brand buyout. The sponsor had been chasing the asset for months and had an exclusivity window closing in. The deal team's thesis was that the brand had a durable premium moat and the category had years of headroom. The functional brief was to confirm it.

The Story

Manas was brought in to run commercial due diligence for a global PE fund on a consumer brand buyout. The sponsor had been chasing the asset for months and had an exclusivity window closing in. The deal team's thesis was that the brand had a durable premium moat and the category had years of headroom. The functional brief was to confirm it.

The consumer research did not support the thesis. Two findings came out of the work. The brand's premium was real, but it was distribution-led rather than affinity-led. In blind preference testing and switching conditions, loyalty was shallower than the market data implied. And the category headroom was concentrated in a price tier the brand had deliberately never played in. Capturing that headroom meant either diluting the premium positioning or building a second brand, neither of which was in the model. Roughly a third of the growth case's volume was coming from a segment the asset had no right to win.

Manas raised this at the interim, not the final readout, when there was still time for the deal team to test it themselves. He framed it precisely: here is the evidence, here is what would have to be true for the thesis to hold, and here is how you could check it in the two weeks remaining.

There was real pressure to describe the finding as conservative, to soften it into a sensitivity rather than challenge the base case. His position was that he would flex the framing but not the finding. If they wanted the number moved, the way to move it was new evidence, not softer language.

The deal proceeded, but at a lower entry price. The second brand moved into the value creation plan and day one work stream rather than remaining an upside lever. The research changed the deal without killing it.